The Financial Post reports in its Saturday, Feb. 16, edition that Canopy Growth managed to lock down nearly a third of Canada's recreational cannabis market last year. The Post's Geoff Zochodne writes that BMO Capital Markets estimates Canopy's recreational sales volume during the quarter ended Dec. 31 represented a market share of 30 per cent. Chief executive officer Bruce Linton expects to "dominate" the weed market in Canada. Rival Aurora Cannabis reportedly had about 20 per cent of the recreational market. Canopy has made a number of acquisitions over the past year, including the purchase of hemp researcher Ebbu. It has vowed to make further investments where it was granted a hemp processing and production licence in January. A subsidiary, Canopy Health Innovations, has begun "in-human" clinical trials to test out the use of medical marijuana in treating insomnia. Canopy reported Friday that it got off to a solid start in the early days of cannabis legalization in Canada, although rising costs associated with breaking into the market dampened some of the enthusiasm. The company booked a profit of $74.9-million for the three months ended Dec. 31, up from $11-million from a year before.